Financial Daily from THE HINDU group of publications
Saturday, Dec 24, 2005


Group Sites

Corporate - Announcements

Aurobindo gets USFDA approval for Stavudine

Our Bureau

Hyderabad , Dec. 23

AUROBINDO Pharma Ltd has announced that the USFDA has granted tentative approval for Stavudine oral solution of one mg.

The company in a statement said that this product will now be available for consideration for purchase under the President's Emergency Plan for AIDS Relief (PEPFAR).

With this approval, Aurobindo now has 9 products under PEPFAR.

The company stated that Stavudine Oral Solution is the first generic version approval of Zerit for Oral solution manufactured by BristolMyers Squibb.

This is a child-friendly product for paediatric use with HIV through to adolescence.

Stavudine is active against the human immunodeficiency virus (HIV) that causes AIDS.

This is used in combination with other agents for treatment of HIV-1 infection, a company statement said.

More Stories on : Announcements

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
ONGC to pay Rs 25 interim dividend — Govt share amounts to Rs 2,642 cr

Tata Daewoo's new truck range debuts in S. Korea
Aurobindo gets USFDA approval for Stavudine
Ford to raise prices 2.5% from mid-Jan
Suryalakshmi Cotton gets IDBI term loan
SEBI exempts Tata Ind from making open offer
NTPC, Reliance case adjourned to Jan 30
Reliance F&O: NSE cancels Jan 17 trading, fixes Jan 18 as ex-date to adjust de-merger
Tata Chem buys 63 pc stake in Brunner for Rs 508 cr
IndianOil diesel unit at Panipat on stream
Hetero Drugs secures Roche sub-licence for Tamiflu — Arrangement offers scope for huge capacities
`Low labour cost factor won't last long'
CSR time
ONGC proposes Rs 800-cr investment to double Assam production

The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | The Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright 2005, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line